Gisèle Lacoste Selected Research

TG4010

2/2016	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
1/2015	Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.
11/2011	Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gisèle Lacoste Research Topics

Disease

3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2016 - 11/2011
2	Neutropenia 02/2016 - 11/2011
2	Fatigue 02/2016 - 11/2011
2	Neoplasms (Cancer) 01/2015 - 05/2008
1	Vaccinia 02/2016
1	Injection Site Reaction 02/2016
1	Disease Progression 01/2015
1	Fever (Fevers) 11/2011
1	Pain (Aches) 11/2011
1	Pleural Effusion (Pleural Effusions) 11/2011
1	Abdominal Pain (Pain, Abdominal) 11/2011
1	Anorexia 11/2011
1	Melanoma (Melanoma, Malignant) 05/2008

Drug/Important Bio-Agent (IBA)

3	TG4010IBA 02/2016 - 11/2011
2	Interleukin-2 (IL2)IBA 02/2016 - 05/2008
1	AntigensIBA 02/2016
1	VaccinesIBA 01/2015
1	Dacarbazine (DIC)FDA LinkGeneric 05/2008
1	Biological ProductsIBA 05/2008

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 02/2016 - 11/2011
1	Immunotherapy 02/2016
1	Therapeutics 01/2015
1	Injections 05/2008